Jennifer Cavitt

Jennifer L. Cavitt

Professor of Clinical Geo

One Stetson Square

2346

COM Neurology Epilepsy - 0525

Stetson Building
Suite 2300
Cincinnati, Ohio 45267-0525

Education

Medical Degree, University of Kansas

Residency, Medical College of Virginia Richmond, VA,

Fellowship, University of Cincinnati (Clinical Neurophysiology)

Bachelor of Arts, University of Kansas 1992 (Human Biology)

Positions and Work Experience

- University of Cincinnati Dept. of Neurology: associate professor in general neurology and epilepsy, 2009 – 2016,

- University of Cincinnati Dept. of Neurology: assistant professor in general neurology and epilepsy, 2004 – 2008,

- University of Cincinnati Dept. of Neurology: clinical instructor in general neurology and epilepsy, 2002 – 2004,

- University of Cincinnati Dept. of Neurology: Professor in general neurology and epilepsy, 2016 – Present,

Research and Practice Interests

Epilepsy, Seizure Disorders, Electroencephalogram (EEG)

Clinical Focus

Clinical Neuropsychology

Neurology

Specialities

Clinical Neurophysiology

Epilepsy

Neurology

Certifications

American Board of Psychiatry and Neurology (Epilepsy)

10/16/2017

American Board of Psychiatry and Neurology (Clinical Neurophysiology)

03/12/2003

American Board of Psychiatry and Neurology (Neurology)

06/29/2002

Research Support

2000 – 2010 Co-investigator of clinical center: Neurodevelopmental effects of antiepileptic drugs. National Institutes of Health. 5R01NS038455. Principal investigator of clinical center: Michael D. Privitera, M.D

2005 – Present Co-Investigator: NIH – Genetic Influences on Human Epilepsy PI: Russell Buono

2008 – present Co-Investigator: An open-label multicenter, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 150 mg/day in subjects aged 16 years or older suffering from epilepsy

2008 – present Co-Investigator: Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome, UCB $60,150. PI David Ficker, M.D.

2008 – present Co-Investigator: Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox-Gastaut Syndrome. PI David Ficker, M.D.

2008 – present A double-blind, placebo-controlled, dose-escalation, parallel-group study to evaluate the efficacy and safety of E207 (perampanel) given as adjunctive therapy in subjects with refractory partial seizures (Eisai Clinical Study Protocol E2007-G000-304)

2008 – present A 14-month open-label extension phase of the double-blind, placebo-controlled, dose-escalation, parallel-group studies to evaluate the efficacy and safety of E2007 (perampanel) given as adjunctive therapy in subjects with refractory partial seizures (Eisai Clinical Study Protocol E2007-G000-307)

Grant: #S980286 \ NS038455 Investigators:Cavitt, Jennifer; Flood-Shaffer, Kellie; Privitera, Michael 08-01-2012 -07-31-2017 National Institute of Neurological Disorders and Stroke Maternal Outcomes and Neurodevelopment Effects of Antiepileptic Drugs (MONEAD) Role:PI $195,174.00 Active Level:Federal

Grant: #61856243-125439 / U01NS038455 Investigators:Cavitt, Jennifer 05-15-2018 -02-28-2023 Stanford University Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Role:PI $93,231.00 Active Level:Institution of Higher Education

Publications

Peer Reviewed Publications

Cavitt,J., Privitera,M. (2004. ) Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence .Archives of Neurology, , 61 (10 ) ,1604 -1607

Shi,F., Cavitt,J., Audus,K. L. (1995. ) 21-Aminosteroid and 2-(Aminomethyl)chromans Inhibition of Arachidonic Acid-Induced Lipid Peroxidation and Permeability Enhancement in Bovine Brain Microvessel Endothelial Cell Monolayers .Free radical biology & medicine, , 19 (3 ) ,349 -357

Thompson,S. E., Cavitt,J., Audus,K. L. (1994. ) Leucine enkephalin effects on paracellular and transcellular permeation pathways across brain microvessel endothelial cell monolayers .Journal of cardiovascular pharmacology, , 24 (5 ) ,818 -825

Privitera M, Cavitt J (2002. ) Identifying and Treating Seizures and Epilepsy .Primary Care Reports, , 8 (24 ) ,210

Shi F, Cavitt JL, Audus KL (1993. ) Characterization of Dextromethorphan and Dextrorphan Uptake by a Putative Glutamic Acid Carrier and Passive Diffusion across Brain Microvessel Endothelium .Drug Delivery, , August ,

Wissel, Benjamin D; Dwivedi, Alok K; Gaston, Tyler E; Rodriguez-Porcel, Federico J; Aljaafari, Danah; Hopp, Jennifer L; Krumholz, Allan; van der Salm, Sandra M A; Andrade, Danielle M; Borlot, Felippe; Moseley, Brian D; Cavitt, Jennifer L; Williams, Stevie; Stone, Jon; LaFrance, W Curt; Szaflarski, Jerzy P; Espay, Alberto J (2016. ) Which patients with epilepsy are at risk for psychogenic nonepileptic seizures (PNES)? A multicenter case-control study.Epilepsy & behavior : E&B, , 61 ,180-184

Honors and Awards

American Epilepsy Society TopScholars Program, December 2001

Most Distinguished Resident Award MCV Dept. of Neurology, June 2001

University of California – San Francisco Headache Preceptorship, June 2000

American Neurological Association Annual Meeting and Resident Symposium, October 1999

Award for Outstanding Resident Teacher, 1999 Department of Neurology, Medical College of Virginia

Mini – Fellowship in Epilepsy Wake Forest University, November 1998

Post Graduate Training and Education

2001-2002 Fellowship, Clinical Neurophysiology, University of Cincinnati, , Cincinnati, OH

1998-2001 Residency, Neurology, Medical College of Virginia, , Richmond, VA

Professional Affiliation

American Epilepsy Society 2002 - present

American Academy of Neurology 1998 – present

American Medical Association 1997 – 1998

Alpha Omega Alpha Medical Honor Society, inducted 1997

Contact Information

Academic - Stetson Building
Suite 2300
Cincinnati  Ohio, 45267-0525
Phone: 513-558-2968
Fax: 513-558-4887
jennifer.cavitt@uc.edu